{"name":"PPD Development, LP","slug":"ppd-development-lp","ticker":"","exchange":"","domain":"ppddevelopmentlp.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Cohort C: bevacizumab","genericName":"Cohort C: bevacizumab","slug":"cohort-c-bevacizumab","indication":"Metastatic colorectal cancer","status":"phase_2"}]}],"pipeline":[{"name":"Cohort C: bevacizumab","genericName":"Cohort C: bevacizumab","slug":"cohort-c-bevacizumab","phase":"phase_2","mechanism":"Bevacizumab is a monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A).","indications":["Metastatic colorectal cancer","Metastatic non-small cell lung cancer","Metastatic renal cell carcinoma","Epithelial ovarian cancer","Glioblastoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPTVI2VzR3U3ZIbmxaLXRkdmdteEJ6Y0xZM0dMRVdXSjU3MnpzeEVDemJHVm5MWW01MGdnU0F1bHk4aE1BSUU5VHJ0RDZKMlJEWDhRM2VCNHpHWVFtVDhMeHNOVTlvVnVoVk50a1BjTmhYYlVtRG9EcmEwdVRleGpORjFZa1M2VC1YLVUwaHdpUXdFd3RtZ0JubVJiQmRaMk1sS0ZINjdvc2otNFdDMV9qVWtFSXFwWW01LVFZd9IBckFVX3lxTFBkSkN1MTY1NVlQZ2tVaGhzb3MzNWQxaENvbjRPNHRfdmVOemthQUR5LVQ0Qm4zMURpbldnNUNfMXp5MF9ZYnZlVVFRVEVBdVNCeFJVLU5YeXgwQXR4QWV6V09uNWtOVVk0M3JDUWxJX1hTUQ?oc=5","date":"2025-07-25","type":"pipeline","source":"Law360","summary":"1st Circ. Backs Ex-Pharma Director's $24M Disability Bias Win - Law360","headline":"1st Circ. Backs Ex-Pharma Director's $24M Disability Bias Win - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPU0h2OURla2dSRUJDbjI0d0pXVFQtRS1YWVZ6NmtiNmZrU2dfTjVaSUZxUmRNYUJzTWx4UGVCVk9od3pvSThjb3g1MFVkeGlWZHdvMktvVEJYc2x5QW04a3Raa3M2ZjVDVElFVmF6Zi1MQ0VidEMzZ29SaG03U29PQWx4SlhfV1Rt?oc=5","date":"2025-03-12","type":"pipeline","source":"Charlotte Observer","summary":"Which NC organizations would be impacted by Trump’s NIH funding cuts? Here’s a list - Charlotte Observer","headline":"Which NC organizations would be impacted by Trump’s NIH funding cuts? Here’s a list","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPZFUxUExHTmV3MGtXaXhGUWZiV0NnRmlDNWkzQVdYZzFVMDVuQlNjRkNTTURuOVdCNVZlUGdocFpEVE01N0ZyNHAxaVI5WkViQ2NOV3FsdFlUdWtPM1ZEaDdseDFFQ1RZN2I5MnpPMXkwei15S01Cel9hVmxuUG15dWtBN3AyTUk?oc=5","date":"2025-02-11","type":"pipeline","source":"Charlotte Observer","summary":"Everything you need to know about NIH cuts (+ how they could cause ‘massive layoffs’ in NC) - Charlotte Observer","headline":"Everything you need to know about NIH cuts (+ how they could cause ‘massive layoffs’ in NC)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPUFpKYVJFbzF3dGd0d0p1NXlDRk5ZMGYzX1JBSW5Cb0pXN19yS0VpRUF6dFU0U05VV2pEYjhKR3hpWXlEMzBWU1FuN2ZPWVhyZ3plV1VBaEF4anB0c01KM25TUEhrM1hNSU01TTA5VTZ4UmV5M1ZYaW1Nd25CN3VMVnU1OWU0dmk3WlhaeHRzejhzU21Ca2x6NTM0d2dKMWp6b1RSeWVUdUY3LU44bFpJeUF6ZmJYM0hmMzdjUg?oc=5","date":"2024-06-24","type":"trial","source":"Contract Pharma","summary":"Edesa’s Paridiprubart Selected for U.S.-Funded Platform Trial in General ARDS - Contract Pharma","headline":"Edesa’s Paridiprubart Selected for U.S.-Funded Platform Trial in General ARDS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPbm9HUzgyZXlab09RS2FZNFlLOGsyTjMwd0oySHFZdlFON0ZkSkNnaWFjdTlLMHk2R1NxYnd3NHR6cWFFUXhNMlMtZUJWOFJobVM0cDNJejZkbmNPYm5TSGlfaXk3UTNndkJXZWg5cWMtWklfSkxMUUpEMmdjQkNObXJBZHdnOXEtUG5lcm81d0RPZnN3MWlFOG8xY2dmSEdmeC11S2hEMEpaaXFUc0t4OWRUckE?oc=5","date":"2023-12-22","type":"trial","source":"BioPharma APAC","summary":"Thermo Fisher's PPD Chosen by BARDA for ARDS Phase II Trial Support - BioPharma APAC","headline":"Thermo Fisher's PPD Chosen by BARDA for ARDS Phase II Trial Support","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQZjBPTHZtRFNKeFJvLW14b2xIQWlvSkJkQmkwTmNmYW5hRGVwRGlKb214aU1CV1ktbVE5a252RXVYV3owWVJQaUd0SGxQRjFuMUM1c0xrdE13Mi1EMWtIYmJBWEh4S1hFbWJnb1RtZFdQSjJJY1M4eW93dWNsSHhQcWRuRkRmLTViREtVRTNfVWV3WTlGekJiRjNZcXIwLW1wd3Vqd0NnWEhIWnU0bkdNZ2xrcjd5d2g10gFyQVVfeXFMTW5YcjJPNWM2MGxvOENGeklsX2R1ZzRIUjRLenRRYlBCUmo3VjBrdkJzRmF0Q2dYdWVOUHBQSlFpX3QyR2ZRcXd5eWRTZkYzOUxmZE9sdkViV2cwTWxhRnhtMU56YjRzcUMtcjVwZ0lIZ0FR?oc=5","date":"2023-04-10","type":"pipeline","source":"Law360","summary":"Ex-Pharma Exec Gets $24M Jury Win In Disability Bias Suit - Law360","headline":"Ex-Pharma Exec Gets $24M Jury Win In Disability Bias Suit - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPbm1EaU9CekNiRF9SMnJLeUlCQmNHdjZJOVFHSzdwd1l3cjJ3elUxNWlJS19lRVllMzVOUEFPR0RxS0dUdDBuUmV0OFk5bkZzZzBjWWhiQjg1WjZ0eXJIZFZ2V0pBZVllemNxN1lMampGalhqTFkzaTNFTkl1ZVVJV3EzOC1RaGRGLVdRYkFvSm5OMnprdkE2TXZ2MU9uZTVWMl9zOHpZb3RsS055dDdzeFh1RQ?oc=5","date":"2021-12-08","type":"pipeline","source":"PR Newswire","summary":"Thermo Fisher Scientific Completes Acquisition of PPD, Inc. - PR Newswire","headline":"Thermo Fisher Scientific Completes Acquisition of PPD, Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxNeGJlVEpUcndUZ1ItWm43cHF4VFdEMjVtMGtXNmFzZDVuRWVueDV5aVNzRW9xRVZ5ejRtOU9BTkN2aW5zMVZfeVJvWVZ5OVlPdFRjRzdVUkRwRTcyc0JCNlRlOHFicXhDRFZncWg0UUFkVm5JYl9QcGNXdHlzRUdHUWNn?oc=5","date":"2021-04-19","type":"pipeline","source":"pehub.com","summary":"Long-hold pays off: H&F, Carlyle make a killing with PPD - pehub.com","headline":"Long-hold pays off: H&F, Carlyle make a killing with PPD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPQ3o2d0hRQnZ6di00OTFuRGx4T1R2TVNsbTR1YkFZdHptNXZENklsaTZYeXVtMThPWi0wOUN2U0FjSTliQW9pMEFPS0NnbTN1X2JJTFRPTFRDY0R0Vl90a3h3QmtYcUxVZHpGVlFUXzVYdFdoSTJRR1NfOVVROHluYUFBMk52SFI0MzBRQ2dWejdlUlFUZnNZWHJEemsyblpMOHNnQ1g0TmtoY2ZGRU5pekQ5MGZtbEl6T3JORmIzWQ?oc=5","date":"2021-04-16","type":"earnings","source":"WilmingtonBiz","summary":"PPD Headquarters: A Big Building With A Bigger Impact - WilmingtonBiz","headline":"PPD Headquarters: A Big Building With A Bigger Impact","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQSGRmQ0RsZndFS1ppLTVYeW5SbjJwOUxOS1JSMTIxbGZISURJSHFHUHJEWHBBYVc3bXJ5OEd4VzJRVVpTcUU5NHpqOXBlbDM2WllRSFludFVTLUh3WU9JNTBjTnBaXzlZekhkbDdWUi1sZ0J2X1pWNmlnQUxJQ0dBRHB0YVZfdnZxOVZ3ZTlRQldBSkdjckhYcG1waXlXTnZibVE?oc=5","date":"2020-12-17","type":"pipeline","source":"pehub.com","summary":"ERT-Bioclinica marriage, led by Nordic and Astorg, pushes valuation to $5.9bn - pehub.com","headline":"ERT-Bioclinica marriage, led by Nordic and Astorg, pushes valuation to $5.9bn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOeEZFTzZOb3FIZnpkbEM4Z19NckxiSFMtRC1mem5Kb2tOZG0zMDVGUDZoNmFkUGlUajdtVFk4RFF5eVhfT3huUzJIb1I2QzA4ZXVOb2ZzaUgwUG9fRlBhajFLUGF6T2NwZWdxdVM3Z0R1VnhaeVRublNpcGQ2U3BHZ3dMZVVJRVpsb0c2QVd5ZDhYeEs0dnhRZjd6MGpzZDA?oc=5","date":"2017-03-29","type":"pipeline","source":"The Edge Malaysia","summary":"PPD's private equity owners in talks to sell stakes — sources - The Edge Malaysia","headline":"PPD's private equity owners in talks to sell stakes — sources","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxONzhrckh5NS1CdmlTb1JNSTVqVHRyb2ZDNDROZVNHSDVoVmllbDlpVFIzdWI0T2pvQ0RmVnpaWi02bW5LbzVwemh5cF9YVTM3MmpFMDA4a2I4dnZfaWZ3WjdCOUlQdFBheURNRmQxMGZlTENZbE9WS20wcFYtOE12cGpJR1VpY2ZzLUo1S3JIQ2dKc1k4RlE?oc=5","date":"2015-12-14","type":"pipeline","source":"BioSpace","summary":"Privately-Held CRO PPD Considering Sale or IPO Valued at $8 Billion - BioSpace","headline":"Privately-Held CRO PPD Considering Sale or IPO Valued at $8 Billion","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}